Melbourne, Australia--(Newsfile Corp. - January 4, 2021) - AdAlta Limited (ASX: 1AD), a clinical stage biopharmaceutical discovery and development company using i-body technology to address challenging drug targets is pleased to announce it is presenting at Biotech Showcase™ 2...

Hingham, MA -- January 4, 2021 -- Applied Tissue Technologies (ATT), an advanced wound care company, announced the publication of a peer reviewed study in Plastic and Reconstructive Surgery Journal®, "Study Comparing Platform Wound Dressing (PWD® ), a Negative-Pressure Device ...

PETACH TIKVA, Israel, January 4, 2021 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that Dr. Sari Fishman, the...

GAITHERSBURG, Md., Dec. 28, 2020 -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced initiation of PREVENT-19, its pivotal Phase 3 study in the United States and Mexico to eval...

HAUPPAUGE, NY (Dec. 24, 2020) – COVAXX, a U.S. company developing UB-612 a multitope peptide-based vaccine to fight COVID-19, today announced an exclusive agreement with Aurobindo Pharma to expand its global development and commercialization of UB-612 to India and the United N...

HAUPPAUGE, NY (Dec. 22, 2020) – COVAXX, a U.S. company developing a multitope synthetic peptide-based vaccine to fight COVID-19, has established a Vaccine Prioritization Advisory Group (VPAG) to guide the company leadership on how best to apportion the first 100 million doses ...

With the arrival of the holiday season, UGI encourages all members of the community to remember the following energy-related safety tips: Practice good safety habits when using your oven and stove.  If you use natural gas for cooking, be sure to keep loose clothing, dish towel...

We have made tremendous progress over the past year to fundamentally improve the position of the company, including cleaning up our capital structure, securing long-term funding, signing critical licensing agreements, accelerating our preclinical development programs towards c...

With the closing of our $12.8 million September 2020 financing, GeoVax is now in the strongest financial position in recent memory. A total of 2,310,000 units were issued at a price to the public of $5.00 per unit consisting of one share of common stock and one five-year warra...

The execution of the Patent and Biological Materials License Agreement with the NIH illustrates our confidence in the MVA-VLP platform. This viral vector provides a level of flexibility to our research efforts that will allow for the design of vaccines that are unique to the m...